The LDN Shop
Visit our e-commerce website for Conferences, Webinars, Medical Membership, eBooks etc
Low-dose naltrexone for post-COVID fatigue syndrome: a study protocol for a double-blind, randomised trial in British Columbia
Hiten Naik et al. Online issue publication May 13, 2024
Exciting breakthrough offers hope for Long COVID patients
Published May 7, 2024
Author Emma O'Connor - Griffith University
https://news.griffith.edu.au/2024/05/07/exciting-breakthrough-offers-hope-for-long-covid-patients/
Addiction Medication Offers New Hope for Long COVID Patients
Featured in Neurology Neuroscience·May 7, 2024
New Research Aims to Unravel Both ME/CFS and Long COVID
Miriam E. Tucker
Medscape Medical News > Conference News
December 21, 2023
A key to a ‘faulty’ lock: Why Aussie researchers are excited about naltrexone for CFS
Ausdoc.com
31 July 2023
https://www.ausdoc.com.au/news/a-key-to-a-faulty-lock-why-aussie-researchers-are-excited-about-naltrexone-for-cfs/
Off-Label Meds: Promising Long COVID Treatments?
Medscape
28 July 2023
https://www.medscape.com/viewarticle/994728?form=fpf
With a lack of FDA-approved treatments, doctors who treat long COVID are turning to off-label use of drugs designed for addiction, diabetes, and other conditions.The FDA approves each drug to treat a specific condition. Off-label use, which is legal and common, allows doctors to prescribe drugs for another use.